Na Li

First-Line Durvalumab Plus Platinum-Etoposide Versus Platinum-Etoposide for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis

Longfeng Zhang, Yongfu Hang, Maobai Liu et al. · Frontiers in Oncology · 2020 · 36 citations · Full text

Cost Effectiveness of Imatinib, Dasatinib, and Nilotinib as First-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia in China

Na Li, Bin Zheng, Hongfu Cai et al. · Clinical Drug Investigation · 2017 · 26 citations

Hematological Malignancy, Medicine, Hematology +6

Dietary diversity and overweight are associated with high intrinsic capacity among Chinese urban older adults (2020−2021)

Siyang Lin, Min Huang, Linxin Yang et al. · Experimental Gerontology · 2023 · 18 citations · Full text

Cost-effectiveness analysis of nivolumab plus ipilimumab <i>versus</i> chemotherapy as the first-line treatment for unresectable malignant pleural mesothelioma

Liu Yang, Xueqiong Cao, Na Li et al. · Therapeutic Advances in Medical Oncology · 2022 · 17 citations · Full text

Cost–Effectiveness Analysis of <i>UGT1A1*6/*28</i> Genotyping for Preventing FOLFIRI-Induced Severe Neutropenia in Chinese Colorectal Cancer Patients

Xiaoxia Wei, Jiaqin Cai, Hong Sun et al. · Pharmacogenomics · 2019 · 15 citations